Safety evaluation of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) for allergic rhinitis.
about
A review of the clinical efficacy and safety of MP-AzeFlu, a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate, in clinical studies conducted during different allergy seasons in the USMP29-02 reduces nasal hyperreactivity and nasal mediators in patients with house dust mite-allergic rhinitis.Olfaction in patients with allergic rhinitis: an indicator of successful MP-AzeFlu therapy.Safety of a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in children: A randomized clinical trial.
P2860
Safety evaluation of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) for allergic rhinitis.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Safety evaluation of MP29-02 ( ...... ionate) for allergic rhinitis.
@en
type
label
Safety evaluation of MP29-02 ( ...... ionate) for allergic rhinitis.
@en
prefLabel
Safety evaluation of MP29-02 ( ...... ionate) for allergic rhinitis.
@en
P2093
P2860
P1476
Safety evaluation of MP29-02 ( ...... ionate) for allergic rhinitis.
@en
P2093
David Price
Jean Bousquet
Ludger Klimek
P2860
P304
P356
10.1517/14740338.2016.1122755
P407
P577
2015-11-19T00:00:00Z